1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow 4.0 mg of DE-122: new trials by email Literature Review of 4.0 mg of DE-122 trials Research Report on 4.0 mg of DE-122
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122 - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Santen Inc. | 12 | 2015-09-16 | 2020-01-14 |
Santen Inc. (1)
United States (1)